Testimony before the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee Regarding Desmopressin for Nocturia

View the Testimony as a PDF.

View the Slide Show as a PDF.

View the Press Release.

Public Citizen strongly opposes Food and Drug Administration (FDA) approval of Nocdurna (desmopressin) — a drug already twice rejected by the FDA — for treatment of nocturia due to nocturnal polyuria in adults because the drug’s serious risks far outweighs its meager clinical benefits.